Drug intelligence / Profile preview

RCI0165

Development stage: Preclinical
Lead developer: Rudacure
Modality: Gene Therapies
Administration: Injection

Overview

RCI0165 is an adeno-associated virus (AAV) vector-based gene therapy developed by Rudacure for the treatment of chronic pain in veterinary patients, specifically companion animals and racehorses. The therapy targets the Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel, which is a key mediator in the transmission of pain signals. By utilizing an AAV vector to deliver genetic material that modulates TRPV1 expression or function, RCI0165 aims to provide long-term relief from chronic pain conditions. It is currently in the preclinical and proof-of-concept stages of development.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on RCI0165.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCI0165.

Explore the full profile